Psychosomatic features of anxiety and depressive disorders

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Somatic symptoms of anxiety and depressive disorders are often encountered in patients presenting to primary care and general outpatient practices. The difficulty of diagnosing such conditions, the inconsistency of their severity with the diagnostic criteria of depressive or anxiety disorders requiring specialized psychiatric care, affect the quality of qualified medical care, increase health care costs, contribute to the chronicization of diseases, deterioration of quality of life and social functioning. An important problem is the safety and effectiveness of therapy of such conditions, preservation of trust in the doctor and the therapeutic process as a whole. The conducted study confirmed the clinical indications for Selank regulatory peptide and its efficacy in the therapy of not only anxiety states, unmotivated anxiety, mood instability, but also somatic manifestations of anxiety and depression, including asthenic, algic (back pain, stomach pain, headache, chest pain) symptom complexes, palpitations, nausea, feeling of weakness, fatigue, sleep disorders and recovery from psychoemotional stress.

Full Text

Restricted Access

About the authors

V. A. Verbenko

V.I. Vernadsky Crimean Federal University

Author for correspondence.
Email: vverbenko@mail.ru
ORCID iD: 0000-0003-2085-6001
SPIN-code: 8787-7098

Professor, MD, S.I. Georgievsky Medical University

Russian Federation, Simferopol

A. A. Dvirsky

V.I. Vernadsky Crimean Federal University

Email: vverbenko@mail.ru
ORCID iD: 0000-0002-1776-2007
SPIN-code: 3868-7330

Professor, MD, S.I. Georgievsky Medical University

Russian Federation, Simferopol

A. A. Soldatenko

V.I. Vernadsky Crimean Federal University

Email: vverbenko@mail.ru
SPIN-code: 4396-3438

S.I. Georgievsky Medical University

Russian Federation, Simferopol

References

  1. Petzschner F.H., Weber L.A., Gard T. et al. Computational Psychosomatics and Computational Psychiatry: Toward a Joint Framework for Differential Diagnosis. Biol Psychiatry. 2017; 82 (6): 421–30. doi: 10.1016/j.biopsych.2017.05.012.
  2. Murray F.M., Toussaint F., Althaus A. et al. Barriers to the diagnosis of somatoform disorders in primary care: protocol for a systematic review of the current status. Syst Rev. 2013; 2: 99. doi: 10.1186/2046-4053-2-99
  3. Leathers C., Kroenke K., Flanagan M. et al. Somatic, Anxiety, and Depressive (SAD) symptoms in young adult Latinx immigrants: prevalence and predictors. J Immigr Minor Health. 2021; 23 (5): 956–64. doi: 10.1007/s10903-021-01218-3
  4. Eilers H., Aan Het Rot M. et al. Childhood trauma and adult somatic symptoms. Psychosom Med. 2023; 85 (5): 408–16. doi: 10.1097/PSY.0000000000001208
  5. Hilderink P.H., Collard R., Rosmalen J.G. et al. Prevalence of somatoform disorders and medically unexplained symptoms in old age populations in comparison with younger age groups: a systematic review. Ageing Res Rev. 2013; 12: 151–6. doi: 10.1016/j.arr.2012.04.004
  6. Becker J.P., Paixao R., Quartilho M.J. Psychopathology and Somatic Complaints: A Cross-Sectional Study with Portuguese Adults. Healthcare (Basel). 2021; 9(4): 478. doi: 10.3390/healthcare9040478
  7. Cruz D., Lichten M., Berg K., George P. Developmental trauma: Conceptual framework, associated risks and comorbidities, and evaluation and treatment. Front Psychiatry. 2022; 13: 800687. doi: 10.3389/fpsyt.2022.800687
  8. Beutel M.E., Wiltink J., Ghaemi Kerahrodi J. et al. Somatic symptom load in men and women from middle to high age in the Gutenberg Health Study – association with psychosocial and somatic factors. Sci Rep. 2019; 9 (1): 4610. doi: 10.1038/s41598-019-40709-0
  9. Guptal K., Singh V., Agarwal S. et al. Somatoform disorders to somatic symptom and related disorders, an overview. Int J Adv Res. 2017; 5 (11): 1109–14. doi: 10.21474/IJAR01/5873
  10. Собенников В.С. Соматизация и соматоформные расстройства. Иркутск, 2014; 304 с. [Sobennikov V.S. Somatization and somatoform disorders. Irkutsk, 2014; 304 p. (in Russ.)].
  11. De Waal M.W., Arnold I.A., Eekhof J.A. et al. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry. 2004; 184: 470–6. doi: 10.1192/bjp.184.6.470
  12. Sansone R.A., Wiederman M.W., Sansone L.A. Adult somatic preoccupation and its relationship to childhood trauma. Violence Vict. 2001; 16 (1): 39–47. doi: 10.1891/0886-6708.16.1.39
  13. Silber T.J., Pao M. Somatization disorders in children and adolescents. Pediatr Rev. 2003; 24 (8): 255–64. doi: 10.1542/pir.24.8.255
  14. Fernandez A., Askenazy F., Zeghari R. et al. Somatic and Posttraumatic Stress Symptoms in Children and Adolescents in France. JAMA Netw Open. 2024; 7 (4): e247193. doi: 10.1001/jamanetworkopen.2024.7193
  15. Glaus J., Moser D.A., Rusconi Serpa S. et al. Families With Violence Exposure and the Intergenerational Transmission of Somatization. Front Psychiatry. 2022; 13: 820652. doi: 10.3389/fpsyt.2022.820652
  16. Khaustova O.O. Psychosomatic masks of anxiety. Ukr Med. Chasopis. 2019; 4 (132): 54–60.
  17. Dmitriev M., Reverchuk I., Glavatskikh M. et al. Medical students' attitudes toward mental stigmatization and its associated with own and familial psychosomatic disorders. E3S Web Conf: Innovative Tech Sci Educ. 2020; 210: 19020. doi: 10.1051/e3sconf/202021019020
  18. Acevedo-Mesa A., Tendeiro J.N., Roest A. et a. Improving the Measurement of Functional Somatic Symptoms With Item Response Theory. Assessment. 2021; 28 (8): 1960–70. doi: 10.1177/1073191120947153
  19. Schneider A., Donnachie E., Zipfel S. et al; Patients With Somatoform Disorders Are Prone to Expensive and Potentially Harmful Medical Procedures-Results of a Retrospective Cohort Study Over 15 Years. Dtsch Arztebl Int. 2021; 118 (25): 425–31. doi: 10.3238/arztebl.m2021.0135
  20. Porcelli P. Psychosomatic Characterization of Adjustment Disorders in the Medical Setting: Some Suggestions for DSM-V. J Affect Disord. 2007; 101 (2007): 251–4. doi: 10.1016/j.jad.2006.11.011
  21. Fava G.A., Freyberger H.J., Bech P. et al. Diagnostic criteria for use in psychosomatic research. Psychother Psychosom. 1995; 63: 1–8. doi: 10.1159/000288931
  22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR. American Psychiatric Association Publishing, 2022.
  23. Thomson K., Randall E., Ibeziako P. et al. Somatoform disorders and trauma in medically-admitted children, adolescents, and young adults: prevalence rates and psychosocial characteristics. Psychosomatics. 2014; 55 (6): 630–9. doi: 10.1016/j.psym.2014.05.006
  24. Van Der Kolk B., Ford J.D., Spinazzola J. Comorbidity of developmental trauma disorder (DTD) and post-traumatic stress disorder: findings from the DTD field trial. Eur J Psychotraumatol. 2019; 10: 1562841. doi: 10.1080/20008198.2018.1562841
  25. Sojka P., Bares M., Kasparek T. et al. Processing of emotion in functional neurological disorder. Front Psychiatry. 2018; 9: 479. doi: 10.3389/fpsyt.2018.00479
  26. Giourou E., Skokou M., Andrew S.P. et al. Complex posttraumatic stress disorder: the need to consolidate a distinct clinical syndrome or to reevaluate features of psychiatric disorders following interpersonal trauma? World J Psychiatry. 2018; 8: 12–9. doi: 10.5498/wjp.v8.i1.12
  27. Harricharan S., Nicholson A.A., Thome J. et al. PTSD and its dissociative subtype through the lens of the insula: anterior and posterior insula resting-state functional connectivity and its predictive validity using machine learning. Psychophysiology. 2020; 57: e13472. doi: 10.1111/psyp.13472
  28. Lanzara R., Scipioni M., Conti C. A clinical-psychological perspective on somatization among immigrants: a systematic review. Front Psychol. 2018; 9: 2792. doi: 10.3389/fpsyg.2018.02792
  29. Lanius R.A., Brand B., Vermetten E. et al. The dissociative subtype of posttraumatic stress disorder: rationale, clinical and neurobiological evidence, and implications. Depress Anxiety. 2012; 29: 701–8. doi: 10.1002/da.21889
  30. Krause-Utz A., Frost R., Winter D. et al. Dissociation and Alterations in Brain Function and Structure: Implications for Borderline Personality Disorder. Curr Psychiatry Rep. 2017; 19 (1): 6. doi: 10.1007/s11920-017-0757-y
  31. Jones M.E., Lebonville C.L., Paniccia J.E. et al. Hippocampal interleukin-1 mediates stress-enhanced fear learning: A potential role for astrocyte-derived interleukin-1β. Brain Behav Immun. 2018; 67: 355–63. doi: 10.1016/j.bbi.2017.09.016
  32. Michopoulos V., Vester A., Neigh G. Posttraumatic stress disorder: A metabolic disorder in disguise? Exp Neurol. 2016; 284 (Pt B): 220–9. doi: 10.1016/j.expneurol.2016.05.038
  33. Kim Y.K., Amidfar M., Won E. A review on inflammatory cytokine-induced alterations of the brain as potential neural biomarkers in post-traumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2019; 91: 103–12. doi: 10.1016/j.pnpbp.2018.06.008
  34. Клинические рекомендации. Генерализованное тревожное расстройство. Российское общество психиатров, 2024 [Clinical guidelines. Generalized anxiety disorder. Russian Society of Psychiatrists, 2024 (in Russ.)].
  35. Клинические рекомендации. Паническое расстройство. Российское общество психиатров, 2024 [Clinical guidelines. Panic disorder. Russian Society of Psychiatrists, 2024 (in Russ.)].
  36. Лалаян T., Коржавина Н. Селанк в лечении болевого синдрома в пояснично-крестцовом отделе позвоночника. Врач. 2014; 9: 30–3 [Lalayan T., Korzhavina N. The influence of Selank on course of pain syndrom in patients with chronic pain syndroms of lumbosacral spine. Vrach. 2014; 9: 30–3 (in Russ.)].
  37. Вербенко В.А., Шакина Т.А. Особенности анксиолитического и стрессопротективного действия пептидного препарата селанк при терапии расстройств адаптации и посттравматического стрессового расстройства. Медицинский алфавит. 2017; 3 (32): 21–6 [Verbenko V.A., Shakina T.A. Effectiveness of new synthesized analogue of endogenous peptide taftcin - Selank in therapy of adjustment and posttraumatic stress disorders. Medical alphabet. 2017; 3 (32): 21–6 (in Russ.)].
  38. Ашмарин И.П., Стукалов П.В., Ещенко Н.Д. Биохимия мозга. СПб: Издательство Санкт-Петербургского университета, 1999; 325 c. [Ashmarin I.P., Stukalov P.V., Yeshchenko N.D. Brain Biochemistry. St. Petersburg: St. Petersburg University Press, 1999; 325 p. (in Russ.)].
  39. Незнамов Г.Г., Зозуля А.А., Сюняков Т.С. и др. Результаты клиникофармакологического исследования ноотропных свойств Селанка – нового анксиолитика пептидной природы. Психиатрия. 2010; 4: 26–35 [Neznamov G.G., Zozulya A.A., Syunyakov T.S. et al. Results of clinical and pharmacologic study of nootropic properties of Selank – a new anxiolytic of peptide nature. Psychiatry. 2010; 4: 26–35 (in Russ.)].
  40. Физические симптомы (PHQ-15) [Электронный ресурс] [Physical Symptoms (PHQ-15) (in Russ.)]. URL: https://www.phqscreeners.com/images/sites/g/files/g10060481/f/201412/PHQ15_Russian%20for%20Russia.pdf
  41. Toussaint A., Kroenke K., Baye F., et al. Comparing the Patient Health Questionnaire – 15 and the Somatic Symptom Scale – 8 as measures of somatic symptom burden. J Psychosom Res. 2017; 101: 44–50 doi: 10.1016/j.jpsychores.2017.08.002
  42. Kroenke K., Spitzer R.L., Williams J.B.W. et al. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry. 2010; 32 (4): 345–59. doi: 10.1016/j.genhosppsych.2010.03.006
  43. Acevedo-Mesa A., Monden R., Castro-Alvarez S. et al. Does Functional Somatic Symptoms Measurement Differ Across Sex and Age? Differential Item Functioning in Somatic Symptoms Measured With the CIDI. Assessment. 2022; 29 (7): 1392–405. doi: 10.1177/10731911211017228

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Severity of somatic symptoms (PHQ-15) during Selank therapy

Download (59KB)
Indexing metadata
3. Fig. 2. Severity of symptoms according to HADS before the start of therapy with Selank and 2 weeks after therapy

Download (62KB)
Indexing metadata

Copyright (c) 2025 Russkiy Vrach Publishing House